Search hospitals

>

New York

>

New York

Columbia University Irving Medical Center

Claim this profile

New York, New York 10032

Global Leader in Cancer

Global Leader in Pancreatic Cancer

Conducts research for Lung Cancer

Conducts research for Solid Tumors

Conducts research for I Am A Healthy Volunteer

358 reported clinical trials

122 medical researchers

Photo of Columbia University Irving Medical Center in New YorkPhoto of Columbia University Irving Medical Center in New YorkPhoto of Columbia University Irving Medical Center in New York

Summary

Columbia University Irving Medical Center is a medical facility located in New York, New York. This center is recognized for care of Cancer, Pancreatic Cancer, Lung Cancer, Solid Tumors, I Am A Healthy Volunteer and other specialties. Columbia University Irving Medical Center is involved with conducting 358 clinical trials across 814 conditions. There are 122 research doctors associated with this hospital, such as Susheel Kodali, MD, Richard Carvajal, MD, Luca Szalontay, MD, and Ran Reshef, MD.

Area of expertise

1

Cancer

Global Leader

Columbia University Irving Medical Center has run 30 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
BRAF positive
2

Pancreatic Cancer

Global Leader

Columbia University Irving Medical Center has run 28 trials for Pancreatic Cancer. Some of their research focus areas include:

Stage IV
Stage III
KRAS positive

Top PIs

Clinical Trials running at Columbia University Irving Medical Center

Cancer

Breast Cancer

Lymphoma

Obesity

Ovarian Cancer

Lung Cancer

Endometrial Cancer

Spinal Muscular Atrophy

Alzheimer's Disease

Insulin Resistance

Image of trial facility.

Abatacept

for Myocarditis

This Trial tests if abatacept can reduce serious heart problems in patients with heart inflammation caused by cancer treatments. Abatacept calms the immune system by preventing certain immune cells from becoming fully active, reducing inflammation and damage. Abatacept has been approved by the US Food and Drug Administration for the treatment of rheumatoid arthritis, with or without methotrexate.

Recruiting

3 awards

Phase 3

11 criteria

Image of trial facility.

Emavusertib +/- Ibrutinib

for CNS Lymphoma

This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory (R/R) hematologic malignancies. This trial will be completed in four parts. In Part A1, emavusertib will be evaluated first in a dose escalating monotherapy setting to establish the safety and tolerability (complete). In Part A2, emavusertib will be evaluated in combination with ibrutinib at 560 milligrams (mg) once daily (QD) or 420 mg QD as indicated by disease (Part A2 complete). Part B will comprise 2 cohorts to assess safety and efficacy of emavusertib in combination with ibrutinib in participants with R/R primary central nervous system lymphoma (PCNSL) who have directly progressed on a bruton tyrosine kinase inhibitor (BTKi). In this part of the study, emavusertib will be dosed at 100 mg or 200 mg twice daily (BID) in combination with ibrutinib in 28-day treatment cycles. Part C will comprise 3 treatment arms in the second-line setting to assess the efficacy and safety of emavusertib monotherapy, ibrutinib monotherapy, and emavusertib in combination with ibrutinib in participants with R/R PCNSL who are naïve to BTKi treatment. In this part of the study, eligible second-line participants with R/R PCNSL who are naïve to BTKi treatment will be randomized 1:1:1 to 1 of 3 treatment arms: (1) emavusertib 200 mg BID, (2) ibrutinib 560 mg QD, or (3) emavusertib 200 mg BID in combination with ibrutinib 560 mg QD.

Recruiting

1 award

Phase 1 & 2

1 criteria

Image of trial facility.

Antibody-Drug Conjugate

for Advanced Cancer

This trial is testing MBRC-101, a new drug, in patients with advanced cancers that haven't improved with other treatments. It aims to find the best dose and check its safety and effectiveness. The study will also observe how the drug behaves in the body and if it causes any immune reactions.

Recruiting

1 award

Phase 1 & 2

16 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Columbia University Irving Medical Center?

Where is Columbia University Irving Medical Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does Columbia University Irving Medical Center accept?

What awards or recognition has Columbia University Irving Medical Center received?